To evaluate the in vitro activity of chiglitazar in different PPAR subtypes from different cellular contexts, reporter gene-based assays were carried out in the human hepatoma SMMC-7721 and human osteosarcoma U2OS cell lines, and the results were compared with that from other known PPAR agonists. Here, PPARA is linked to hepatocellular carcinoma.